Ricevi le ultime notizie sulle azioni Exicure con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di XCUR

Ultime notizie per

Exicure

Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

IGC Pharma

Pre-Market Outlook

PRGS

QMCO

VERO

XCUR

Mentre i mercati USA si muovono, alcuni titoli sono già sotto i riflettori. Analisi delle azioni da monitorare oggi.

Progress Software, Exicure e altre 3 azioni da tenere d&#39;occhio oggi

Cinque azioni da tenere d&#39;occhio oggi, inclusi Darden Restaurants e FedEx, con risultati trimestrali pronti a sorprendere.

Pre-market: 5 titoli da monitorare oggi C

Earnings

News

Markets

Trading Ideas

CODA

RFIL

VNCE

Coda Octopus, Exicure e altri titoli in movimento nel pre-market: ecco cosa aspettarsi oggi 16 settembre 2024.

Pre-market: 5 titoli da monitorare oggi, 16 settembre 2024

Exicure Inc

Curate

Press Releases

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Exicure, Inc. Reports Second Quarter 2025 Financial Results

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

FibroGen

Kezar Life Sciences

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma Co

LAVA Therapeutics

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PepGen

Pluri

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Propanc Biopharma

RenovoRx

Senti Biosciences

Tenax Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

Comments

Exicure Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO